The subgroup of patients with methylated MGMT promoter in the primary tumor displayed a significant loss of methylation if treated with concurrent RT/TMZ (7 of 8) compared to patients treated with RT followed by sequential TMZ (1 of 5, p = 0.03). The gene discussed is MGMT; the disease is neoplasm.